How fast a cancer is growing can greatly change options. Focal therapies, which don’t target the entire prostate, are best ...

Protara Therapeutics (NASDAQ:TARA) on February 23, 2026, announced updated interim data from its ongoing Phase 2 ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

Cancer treatment costs declined as much as 8.2% in cities where most hospitals published complete pricing data for oncology services, new research shows, indicating that federal price transparency ...

The company reported strong efficacy and a clean safety profile from its ongoing Phase 2 Advanced-2 bladder cancer trial.

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

A new long-term study has revealed a hidden cost of one of the most widely used chemotherapy treatments. Researchers from the University of South Florida and Indiana University found that many cancer ...

Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...

ImmunityBio shares surge on 700% revenue growth driven by sales of Anktiva, the company's approved drug for bladder cancer.

UConn Center on Aging researchers have published a new editorial in the journal Aging titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In ...

Despite their renal and cardiovascular protection, GLP-1RA vs SGLT2i carries somewhat higher risks of renal cell carcinoma and urothelial cell carcinoma in adults with type 2 diabetes. The risks of ...

Bladder cancer is the sixth most common cancer in the U.S. People diagnosed with bladder cancer in northwestern Pennsylvania ...